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The predicted amino acid sequence of the biosynthetic precursor of dermorphin, a highly potent and nearly specitic 
p-opioid peptide from amphibian skin, contains four repeats of the dermorphin progenitor sequence and one single copy 
of a different heptapeptide sequence. We have developed a specitic enzyme immunoassay and used synthetic peptides 
to detect and purify the new predicted heptapeptide (2.4 rg/g dry skin) from the skin of the Phyllomedusa s uvagei frog 
from which dermorphin was originally isolated The identity of the novel prodermorphin related peptide, Tyr-D-Met- 
Phe-His-Leu-Met-AspNHz, was established by co-chromatography with synthetic peptides on reversephase HPLC, im- 
munological analysis, gas-phase sequencing, mass spectrometry and by pharmacological ssays. Opioid-binding assays 
in vitro demonstrated that both the natural and synthetic heptapeptides displayed exceptionally high selectivity and affmi- 
ty towards the &opioid receptors. Because of its origin and its S-opioid (enkephalin) activity and specificity, this novel 
D-amino acid containing peptide is named dermenkephalin. 
Opioid receptor, a-; Amino acid containing peptide, D-; Dermorphin; Dermenkephalin 
1. INTRODUCTION 
The dermatous glands of amphibians synthesize 
and expel a rich variety of biologically active pep- 
tides [1,2]. Among secretory peptides isolated 
from amphibian skin, dermorphin [3] - Tyr-D- 
Ala-Phe-Gly-Tyr-Pro-Ser-NHz - is the most selec- 
tive high-affinity endogenous k-opioid agonist 
known to date [3-91. With a cDNA library 
prepared from the skin of the South American frog 
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Phyliomedusa sauvagei, the primary structure of 
the dermorphin biosynthetic precursor was elu- 
cidated recently [IO]. The precursor (fig.1) was 
shown to code for a repetitive pattern of five exten- 
sively homologous sequences of about 35 amino 
acids, four of which code for dermorphin while the 
fifth codes for a different heptapeptide sequence 
flanked by the same processing signals as those 
flanking the dermorphin progenitor sequences. 
Assuming the same processing cascade involved as 
for the release of dermorphin, processing of pro- 
dermorphin is expected to yield, beside four copies 
of dermorphin, one single copy of a new C- 
terminally amidated heptapeptide containing a D- 
amino acid residue at the second position i.e., Tyr- 
D-Met-Phe-His-Leu-Met-Asp-NHz. 
Using synthetic peptides in biological and phar- 
macological assays, we have aiready shown [l l] 
that this putative new heptapeptide, named der- 
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Fig. 1. Schematic representation of the structural organisation 
of the dermorphin biosynthetic precursors from the frog 
Phyllomedusa suuvagei [lo]. The N-terminal dashed sequence is 
the predicted signal peptide sequence. Positions of dermorphin 
progenitor sequence, Tyr-Ala-Phe-Gly-Tyr-Pro-Ser, which is 
flanked by Lys-Arg at the amino end and by Gly-Glu-Ala-Lys- 
Lys at the carboxyl end, are shaded. One of the precursors 
(upper representation) has a dermorphin copy replaced with a 
distinct progenitor sequence, Tyr-Met-Phe-His-Leu-Met-Asp, 
whose processing yields dermenkephalin, i.e. Tyr-D-Met-Phe- 
His-Leu-Met-Asp-NHz. 
menkephalin, acts as a highly potent and fully 
selective agonist for the 6-opioid receptor. In this 
study, we report on the isolation and purification 
of dermenkephalin from the skin of Phyllomedusa 
sauvagei as characterized by its chemical structure 
and pharmacological properties. 
2. MATERIALS AND METHODS 
2.1. Peptide synthesis 
Dermenkephalin and analogs were prepared in our 
laboratory as described previously [ 11,121 by stepwise manual 
solid-phase synthesis using the preformed symmetric anhydride 
technique. Homogeneity of synthetic products was assessed by 
analytical RP-HPLC, thin-layer chromatography, amino acid 
analysis and fast atomic bombardment mass spectrometry as 
described [12]. 
2.2. Immunogen preparation and immunization 
The side chain carboxyl of aspartate at the C-terminal end of 
DREK was coupled to BSA for immunogen preparation via 
amide bond, with prior formation of NHS ester [13]. To 100 ~1 
DREK (10 rmol) were successively added 100~1 NHS 
(lOOymo1) and 100 pl DCC (lOpmo1) all in anhydrous 
dimethylformamide (DMF). The mixture was left to react in the 
dark at 22°C for 18 h under continuous stiiring, then added to 
7 ml (21 mg) BSA in 0.1 M borate buffer, pH 9, and 30 min 
later, the reaction mixture was dialysed against NaCl (0.9%). 
About 1 mg of immunogen (DREK-BSA conjugate) in 1 ml 
NaCl (0.9%) was emulsified with 1 ml Freund’s complete adju- 
vant (Difco Lab., Detroit, MI). The emulsion was injected in- 
tradermally into the flank area of 3 New Zealand white rabbits 
at multiple sites (30-40 points). Rabbits were boosted 3 times 
at 6 week intervals then bled ten days after each boosting. Sera 
were screened for antibodies using the enzyme immunoassay 
procedure. The bleedings collected after the fourth booster were 
selected to obtain antisera for routine EIA. 
2.3. Preparation of the enzymatic tracer and the EIA 
procedure 
DREK was coupled to acetylcholinesterase (AChE; EC 
3.1.1.7) from the electric organ of electric eel Electrophorus 
electricus as previously described for DRM [14]. The enzymatic 
tracer was either stored at -80°C or freeze dried and kept at 
4°C until use. Solid-phase EIA was performed with Titertek 
microtitration equipment (Flow Laboratories, Finland) which 
included an automatic plate washer (Microplate Washer 120), 
an automatic plate dispenser (Autodrop) and an automatic 
plate reader (Multiskan MC). All assays were performed in the 
following EIA buffer: 0.1 M phosphate buffer, pH 7.4, con- 
taining 0.4 M NaCl, 1 mM EDTA, 0.1% BSA and 0.01% 
sodium azide. The detailed EIA procedure was described 
elsewhere [1.5]. In short, 96 well microtiter plates (Nunc 96F, 
Denmark) were coated with mouse monoclonal antibodies 
specific to rabbit IgG in order to ensure separation between 
bound and free moieties of the tracer [16]. Before use, the plates 
were washed with 10 mM phosphate buffer, pH 7.4, in the 
presence of 0.05% Tween 20. Reagents were dispensed in the 
following order: 50~1 standard or biological extract, 50~1 
DREK-AChE conjugate and 50 ~1 DREK antiserum l/l0000 all 
diluted in EIA buffer. The plates were left at 4°C for 18 h and 
washed again as above, then 200 pl of Ellman’s medium [17] 
were dispensed into each well. The reaction was allowed to take 
place for 1 h and the absorbance measured at 414 nm with a 
Multiskan MC spectrophotometer. 
2.4. Characteristics of the dermenkephalin enzyme- 
immunoassay 
A typical sensitivity curve for DREK-EIA is shown in fig.2. 
Precision profile studies [18] indicated a coefficient of variation 
inferior to 10% in the interval between 2 and 250 fmol/well. 
The minimum detectable value (considered to be the 
dermenkephalin quantity that decreases the B, value 3 standard 
deviations) is of less than 2 fmol/well, i.e. 2 pg dermen- 
kephalin. The specificity of the selected anti-DREK antiserum 
was investigated using various synthetic dermenkephalin 
analogs (table 1). The low cross reactivity (CR) values (<O.l o/o) 
of analogs where D-Met in the second position was replaced 
with either L-Met or D-Ala indicate the strict need of D-Met for 
antibody recognition of DREK. Changes occurring at the car- 
boxy end were much less critical as shown by the relatively high 
CR values (60-75%) when Asp-NH2 in seventh position was 
replaced with either Asp-OH or Asn-NH2, or when Met in the 
sixth position was either oxidized or replaced with D-Met. Der- 
morphin presented no significant cross reactivity (<O.Ol%). 
The minimum structure to maintain high antibody recognition 
(20%) is DREK-(I-6)-NH2, stepwise deletion of amino acids at 
dermenkephalin’s carboxy end led to proportional oss of cross 
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Fig.2. Typical standard curve obtained for routine EIA. E and Be represent he bound enzyme activity measured respectively in the 
presence or absence of synthetic DREK and LOGIT B/B0 is the corresponding linear transformation. The parallel intermingled curve 
was obtained with the purified natural counterpart. (Inset) Synthetic dermenkephalin was used to construct a calibration curve where 
optical density at 220 nm was plotted against nmol DREK. 
Table 1 
Cross reactivity of dermenkephalin analogs 
No. Peptide sequence Abbreviated %CR” 
Pl Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 DREK loo 
P2 Tyr-L-Met-Phe-His-Leu-Met-Asp-NH2 [L-Met’]-DREK 0.05 
P3 Tyr-D-Ala-Phe-His-Leu-Met-Asp-NH* [D-Ala’]-DREK 0.02 
P4 Tyr-D-Met(o)-Phe-His-Leu-Met(o)-Asp-NH2 [D-Met2(o),Met6(o)]-DREK 30 
P5 Tyr-D-Met-Phe-His-Leu-Met-Asp-OH DREK-(OH) 60 
P6 Tyr-D-Met-Phe-His-Leu-Met-Asn-NH2 [Asn’]-DREK 60 
P7 Tyr-D-Met-Phe-His-Leu-Met(o)-Asp-NH* [Met6(0)]-DREK 75 
P8 Tyr-D-Met-Phe-His-Leu-D-Met-Asp-NH* [D-Met’$DREK 60 
P9 Tyr-D-Met-Phe-His-Leu-Met-NH2 DREK-(I-6)-NH2 20 
PlO Tyr-D-Met-Phe-His-Leu-NH2 DREK-(I-5)-NH2 2 
PI1 Tyr-D-Met-Phe-His-NH* DREK-( l-4)-NH2 0.05 
P12 Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 DRM <O.Ol 
a Using the Abraham criterion [22], the cross reactivity (CR), expressed in terms of percent 
cross reactivity (%CR), is defined as the percent molar concentration at 50% B/B, of the 
peptide tested compared to that of DREK whose %CR is set to be 100 
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reactivity and oxidized Met at both second and sixth positions 
retained 30% cross reactivity. 
2.5. Preparation of biological sample 
Five dry skins (1 g/skin) of the frog Phylomedusa sauvagei 
were minced with scissors and extracted twice for a week with 
20 vols (v/w) of 80% methanol/water at 4°C under continuous 
stirring. Combined extracts were centrifuged for 40 min at 
40000 x g and the supernatant evaporated under vacuum. 
2.6. Chromatographic characterization of immunoreactive 
material 
The dried methanol extract was dissolved in 10% acetic acid 
and fractionated on a previously calibrated gel filtration 
Sephadex G15 column. Immunoreactive fractions that coeluted 
with synthetic DREK were pooled, freeze dried, dissolved in 
0.1% trifluoroacetic acid/water and refractionated on a RP- 
HPLC (Lichrosorb C18, 10/m, 250 x 4.6 mm) column. Elu- 
tion was achieved with a O-60% linear gradient of acetonitrile 
in 0.1% TFA/water along 60 min at a flow rate of 1 ml/min 
(fig.3A). Immunoreactive fractions that coeluted with synthetic 
DREK were pooled, freeze dried, dissolved in 25% acetonitrile/ 
water containing 0.1 Vo TFA and refractionated on the same col- 
umn but eluted with a 25-35% linear gradient of acetonitrile in 
0.1% TFA/water along 50 min (fig.3B). Immunoreactive frac- 
tions that coeluted with synthetic DREK were submitted to a 
final purification step on a Lichrosorb C18, 5pm (250 x 
4.6 mm) column eluted with a slow linear gradient of 25-32070 
acetonitrile in 0.1% TFA/water for 60 min (fig.3C). 
2.1. Sequence analysis 
Sequence determination was carried out on an Applied 
Biosystems 470 gas-phase peptide sequenator. Phenylthio- 
hydantoin amino acids were detected with an on-line Applied 
Biosystems 120 A analyzer. Data collection and analysis were 
performed with an Applied Biosystems 900 A module 
calibrated with 25 pmol phenylthiohydantoin amino acids 
standards. 
2.8. Opioid-binding assay 
The preparation of the particulate rat brain membrane frac- 
tion has been previously described [8]. Binding assays were per- 
formed at 24°C in 50 mM Tris-HCl, pH 7.4, plus 0.1% BSA 
and 0.01% bacitracin as described [9,11] using [3H]DTLET 
(60 Ci/mmol, CEN Saclay, France) or [‘Hldermorphin 
(52 Ci/mmol) [8] as primary ligands. All determinations were 
performed in duplicate. The 50% inhibitory concentration 
values (ICsc) were obtained from non-linear least-squares 
regression of a 2 parameters logistic equation of the Vo specific 
binding versus logarithm of the dose curves. Inhibitory con- 
stants Ki were calculated from the Cheng-Prusof equation [19]. 
3. RESULTS AND DISCUSSION 
Using a series of RP-HPLC runs operating with 
successively slow gradients of the same solvent 
system, the skin extract was gradually fractionated 
and the purification scheme is summarized in fig.3. 
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Fig.3. Purification scheme of DREK from skin extract of 
Phyilomedusa sauvagei and the elution positions of some 
synthetic analogs (refer to table 1). Absorbance is represented 
as straight lines and the immunoreactive fractions are 
represented as bars. (a) Immunoreactive fractions that co-eluted 
on G15 with synthetic DREK were recovered and injected onto 
a Lichrosorb C18, 10~m (250 x 4.6 mm) column and eluted 
with a linear gradient of O-60% acetonitrile along 60 min at a 
flow rate of 1 ml/min. (b) HPLC of fractions 41-44 from 
chromatogram A eluted with a linear gradient of 25-35% 
acetonitrile. (c) HPLC of fractions 43-44 from chromatogram 
B injected onto a Lichrosorb C18, 5 pm (250 x 4.6 mm) column 
and eluted with a linear gradient of 25-32% acetonitrile. (Inset) 
Mass spectrum of Pl (0.25 /g natural DREK by EIA) showing 
a peak corresponding to [M + H] = 956. 
Synthetic dermenkephalin, dermorphin and 
related analogs were used as molecular markers. 
Two identification criteria were used to search for 
natural dermenkephalin. Fractions collected at 
each HPLC run were tested with the DREK-EIA 
procedure and the immunoreactive fractions that 
co-eluted with synthetic dermenkephalin were 
selected to undergo further fractionation. The 
other immunoreactive fractions observed (fig.3) 
due to cross reactivity of DREK-antibodies with 
DREK-related peptides were separated in the 
subsequent runs and their characterization will be 
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reported elsewhere. The immunoreactive fractions 
that co-eluted with synthetic DREK after the third 
purification step (fig.3C) were used for chemical 
and pharmacological analysis. On the basis of op- 
tical density and EIA (fig.2), we estimated the ex- 
tract to yield 2.4 ,ug DREK (at least 80% pure)/g 
dry skin. 
The sequence of Pl (fig.3c), the endogenous im- 
munoreactive peptide (0.5 pg by EIA) was deter- 
mined up to the seventh residue as Tyr-Met-Phe- 
His-Leu-Met-Asp by automated Edman degrada- 
tion with a gas-phase sequencer. Since the se- 
quence analysis does not yield information on the 
presence of a C-terminal amide group, the en- 
dogenous heptapeptide (0.25 pug by EIA) was fur- 
ther subjected to fast atom bombardment mass 
spectrometry. An unequivocal pseudo-molecular 
ion [M + H]+ = 956 was observed (inset fig.3c) in 
the positive ion mode corresponding precisely to 
that expected theoretically for the sequence Tyr- 
Met-Phe-His-Leu-Met-Asp-NH2. Moreover, syn- 
thetic DREK-OH (P2) behaved chromatographi- 
tally differently from natural and synthetic 
dermenkephalin (fig.3c). 
The presence of a D-methionine at the second 
position was unambiguously established by phar- 
macological, immunological and chromatographi- 
cal criteria. The endogenous DREK isolated from 
skin extracts was tested for its ability to displace 
the prototypical &opioid ligand [3H]DTLET [20] 
from rat brain membrane preparations. As shown 
in fig.4, natural DREK inhibited the high-affinity 
specific [‘HIDTLET binding to S-opioid sites in a 
concentration dependent manner with a Ki of 
1.06 nM and a quasi-Hill coefficient close to unity 
(table 2). The & of natural DREK was almost 
identical to that determined for synthetic DREK 
under similar experimental conditions (fig.4 and 
table 2). In contrast, the highly ,u-selective opioid 
peptide [3H]dermorphin [9] was displaced with 
very low potency by DREK (table 2). On the other 
hand, [L-Met’]DREK was found to be virtually in- 
active in displacing both p- and S-opioid probes 
(table 2), a situation already encountered with [L- 
Ala’]dermorphin [7]. As shown in fig.3, synthetic 
[L-Met’]DREK (P2) behaves chromatographically 
very differently from DREK (Pl) on RP-HPLC 
run under 3 distinct elution conditions. In addi- 
tion, whereas natural DREK diluted parallel to 
synthetic DREK in DREK-EIA assay (fig.2), the 
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Fig.4. Inhibition of [‘HIDTLET specific binding (1 nM) to rat 
brain membranes (0.74 mg/ml of membrane proteins) by 
increasing concentrations of natural dermenkephalin (o), 
synthetic dermenkephalin (0), DTLET (A) and dermorphin 
(A). The percentage of specific binding was calculated as 100 x 
(Es - B,,)/(B, - B,,), where & and B, are respectively the 
amount bound in the presence or absence of competing 
compound, and B. is the non-specific binding, i.e., the binding 
in the presence of 1000 nM unlabeled DTLET. The solid lines 
are theoretical fits to a simple binding isotherm determined by 
non-linear least-squares regression analysis. The data shown are 
for a single representative xperiment. Values for ICsa were 
determined by regression analysis based upon 2-4 independent 
experiments carried out in duplicate. 
Table 2 
Potencies of natural and synthetic dermenkephahn i inhibiting 
the binding at the 6 ([3H]DTLET, 1 nM) and the fi sites 
([“Hldermorphin, 0.5 nM) in homogenates of rat brain at 24°C 
in 50 mM Tris-HCI buffer, pH 7.4 
Ligand Kia (nM) KiG)/Ki(J)b 
[3H]DTLET [3H]Dermorphin 
DTLET 6.0 (0.7) 25.5 (3.5) 4.2 
Dermorphin 359 (31) o.73c (0.02) 0.002 
DREK (synthetic) 1.77 (0.08) 619’ (56) 350 
DREK (natural) 1.06 (0.11) n.d.d 
[L-Me?]DREK’ 3141 (449) 3374 (151) 1.1 
The inhibitory constant Ki was calculated from ICSO values 
using the Cheng-Prussof equation [19]. Reported values are 
the mean of 2-4 experiments carried out in duplicate. Values 
in parentheses are SEM 
The selectivity ratio at the 6 site is expressed as the ratio, Ki 
for p (vs [‘H]dermorphin)/Ki for 6 (vs [‘HIDTLET) 
Taken from [ll] 
Not determined due to low amount of natural 
dermenkephalin 
Taken from [21] 
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very low cross reactivity value (0.0970) of [L- 
Met2]DREK in DREK-EIA indicated the strict re- 
quirement of the D-configuration of the 
methionine residue in position 2 for antibody 
recognition (table 1). 
In conclusion, we have isolated from amphibian 
skin an heptapeptide having a D-Met residue in 
position 2 which stereospecifically binds with high 
affinity and specificity to the S-opioid receptor. 
The identity of this new pro-dermorphin related 
peptide was established by co-chromatography 
with synthetic DREK on reverse-phase HPLC, im- 
munological analysis, sequence determination, 
mass spectrometry and by pharmacological assay. 
Pro-dermorphin thus offers a surprising example 
of an opioid biosynthetic precursor that simul- 
taneously generates two D-amino acid containing 
peptides which behave as highly potent and 
specific agonists for the ,u (morphine)- and S 
(enkephalin)-opioid receptors, respectively. In ad- 
dition, because DRM and DREK have no struc- 
tural features in common with the sequence of all 
the hitherto known opioid peptides, they should be 
useful tools for identifying conformational deter- 
minants for high affinity and selective binding of 
opioids to the p- and J-receptors [21]. 
NOTE ADDED IN PROOF 
During the preparation of this manuscript, Kreil 
et al. [23] have reported on the isolation of a pep- 
tide from amphibian skin whose structure and 
pharmacological activity appear to be essentially 
similar to those of dermenkephalin. This peptide 
was named deltorphin by these authors. 
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